In 2017, the market size of Intrahepatic Cholangiocarcinoma (ICCA) in the 7MM was USD 99.78 million.
The total incident population of Intrahepatic Cholangiocarcinoma (ICCA) in 7MM was 10,177 in 2017. The incident cases of ICCA in the US were found to be 3,639 while Italy and Germany had 1,111 and 1,101 incident cases of ICCA.
Rising Incidence, technological advancements in the identification of biomarkers and increasing R&D activities are some of the key market drivers for Intrahepatic Cholangiocarcinoma.
Some of the key companies in the Intrahepatic Cholangiocarcinoma (ICCA) market include Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology, QED Therapeutics, Janssen Pharmaceutical, Taiho Oncology, RedHill Biopharma, GlaxoSmithKline, Merck, Eisai, Taiho Pharmaceutical, Sorrento Therapeutics, Yuhan Corporation, Hutchison Medipharma, Jiangsu HengRui Medicine, AstraZeneca, Eli Lilly, Servier Laboratories, Forma Therapeutics, and Array BioPharma.
Source: Intrahepatic Cholangiocarcinoma Market Size and Trends Analysis